Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?
Although chemotherapy of tumours has scored successes, drug resistance remains the major cause of death of cancer patients. Initial treatment often leaves residual disease, from which the tumour regrows. Eventually, most tumours become resistant to all available chemotherapy. I call this pan-resista...
Main Author: | Piet Borst |
---|---|
Format: | Article |
Language: | English |
Published: |
The Royal Society
2012-01-01
|
Series: | Open Biology |
Subjects: | |
Online Access: | https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.120066 |
Similar Items
-
Epithelial-mesenchymal Transition and Tumor Drug Resistance
by: Linlin ZHANG, et al.
Published: (2013-01-01) -
Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial–mesenchymal transition
by: Chen D, et al.
Published: (2016-09-01) -
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
by: Bowen Du, et al.
Published: (2016-07-01) -
Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
by: Kakeru Hisakane, et al.
Published: (2021-06-01) -
Metabolic Plasticity and Epithelial-Mesenchymal Transition
by: Timothy M. Thomson, et al.
Published: (2019-07-01)